Content about Mylan Labs

February 23, 2012

The Food and Drug Administration has given tentative approval to a division of Mylan for a generic drug for treating HIV and AIDS in children in developing countries.

PITTSBURGH — The Food and Drug Administration has given tentative approval to a division of Mylan for a generic drug for treating HIV and AIDS in children in developing countries.

Mylan said Thursday that the FDA had tentatively approved Mylan Labs' abacavir sulfate and lamivudine tablets in the 60 mg/30 mg strength. The drug is a generic version of Viiv Healthcare's Epzicom and was approved under the President's Emergency Plan for AIDS Relief. The drug will only be available for purchase in certain developing countries outside the United States.

December 2, 2011

Under the President's Emergency Plan for AIDS Relief, the Food and Drug Administration has given tentative approval to a generic HIV and AIDS drug made by Mylan, the company said.

PITTSBURGH — Under the President's Emergency Plan for AIDS Relief, the Food and Drug Administration has given tentative approval to a generic HIV and AIDS drug made by Mylan, the company said.

The drug maker's Mylan Labs subsidiary received tentative approval for atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength. The FDA's tentative approval of the drug under PEPFAR means it will be eligible for purchase in certain developing countries.

October 19, 2011

Mylan's India-based subsidiary is changing its name, Mylan said Wednesday.

PITTSBURGH — Mylan's India-based subsidiary is changing its name, Mylan said Wednesday.

The generic drug maker announced that Matrix Labs, based in Hyderabad, India, had formally changed its name to Mylan Labs.

"We are pleased to complete the name change from Matrix to a Mylan company and are excited to operate in India under one powerful brand," Mylan chairman and CEO Robert Coury said.

Mylan acquired Matrix in 2006.

September 26, 2010

Winc Design is launching its Charlie Banana brand of environmentally friendly cloth diapers and baby...

Like a freighter in the Atlantic Ocean during hurricane season, anyone with a stake in the generic drug industry will encounter smooth and bumpy sailing alike over the next few years, according to a recent presentation by an industry expert.